|
HOXD-AS1
|
Cervical cancer
|
Cisplatin
|
HOXD-AS1 enhances chemoresistance of cisplatin-resistant cancer cells by modulating miR-130a-3p/ZEB1 axis
|
[142]
|
|
DLX6-AS1
|
Breast cancer
| |
DLX6-AS1 promotes cisplatin resistance through miR-199b-5p/PXN signaling
|
[143]
|
|
NCK1-AS1
|
Osteosarcoma
| |
NCK1-AS1 knockdown enhances Cisplatin sensitivity of cancer cells by regulating miR-137
|
[144]
|
|
SLC7A11-AS1
|
Pancreatic cancer
|
Gemcitabine
|
SLC7A11-AS1 promotes Gemcitabine-resistance by Blocking SCF β-TRCP-Mediated Degradation of NRF2
|
[145]
|
|
SBF2-AS1
|
Pancreatic cancer
| |
SBF2-AS1 promotes the expression of TWF1 by binding with miR-142-3p to induce gemcitabine resistance
|
[146]
|
|
LOXL1-AS1
|
Prostate cancer
|
Doxorubicin
|
LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance
|
[147]
|
|
FOXC2-AS1
|
Osteosarcoma
| |
FOXC2-AS1 promotes doxorubicin resistance by increasing the expression of FOXC2
|
[148]
|
|
AFAP1-AS1
|
Breast cancer
|
Trastuzumab
|
AFAP1-AS1 promotes trastuzumab resistance by binding with AUF1 and activating ERBB2 expression
|
[149]
|
|
SBF2-AS1
|
Glioblastoma
|
Temozolomide
|
SBF2-AS1 enhances chemoresistance to temozolomide by functioning as a ceRNA for miR-151a-3p
|
[150]
|
|
ADAMTS9-AS2
|
Glioblastoma
| |
ADAMTS9-AS2 promotes Temozolomide Resistance via Upregulating the FUS/MDM2 Ubiquitination Axis
|
[151]
|
|
NR2F1-AS1
|
Liver cancer
|
Oxaliplatin
|
NR2F1-AS1 regulates oxaliplatin resistance by targeting ABCC1 via miR-363
|
[152]
|
|
DSCAM-AS1
|
Breast cancer
|
Tamoxifen
|
DSCAM-AS1 enhances Tamoxifen resistance by functioning as a sponge of miR-137
|
[153]
|
|
ADAMTS9-AS2
|
Breast cancer
| |
ADAMTS9-AS2 enhances tamoxifen resistance by activating miR-130a-5p
|
[154]
|
|
AFAP1-AS1
|
Prostate cancer
|
Paclitaxel
|
AFAP1-AS1 modulates the sensitivity of paclitaxel via miR-195-5p/FKBP1A axis
|
[155]
|
|
DDX11-AS1
|
Esophageal cancer
| |
DDX11-AS1 promotes resistance cancer cells to Paclitaxel by inhibiting TOP2A expression via TAF1
|
[156]
|
